Roche to shed 170 jobs in diagnostics restructuring

Roche ($RHHBY) plans to cut 170 jobs in the U.S. and Germany as it winds down the applied sciences business in its lagging diagnostics division. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.